Shares of Biogen BIIB gained 9.5% on Dec 29 following news on its potential acquisition by the South-Korean conglomerate Samsung Group. Per an article in The Korean Economic Daily, the U.S.-based ...

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ ®, a biosimilar to Lucentis 1 (ranibizumab), in Europe. Samsung Bioepis has been working to ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...